- Home
- BCAB vs NOM Comparison
BCAB vs NOM Comparison
Compare BCAB & NOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- NOM
- Stock Information
- Founded
- BCAB 2007
- NOM 1993
- Country
- BCAB United States
- NOM United States
- Employees
- BCAB N/A
- NOM N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- NOM Investment Managers
- Sector
- BCAB Health Care
- NOM Finance
- Exchange
- BCAB Nasdaq
- NOM Nasdaq
- Market Cap
- BCAB 31.5M
- NOM 26.0M
- IPO Year
- BCAB 2020
- NOM N/A
- Fundamental
- Price
- BCAB $0.79
- NOM $11.00
- Analyst Decision
- BCAB Hold
- NOM
- Analyst Count
- BCAB 3
- NOM 0
- Target Price
- BCAB $1.00
- NOM N/A
- AVG Volume (30 Days)
- BCAB 953.7K
- NOM 6.9K
- Earning Date
- BCAB 11-06-2025
- NOM 01-01-0001
- Dividend Yield
- BCAB N/A
- NOM 3.39%
- EPS Growth
- BCAB N/A
- NOM N/A
- EPS
- BCAB N/A
- NOM N/A
- Revenue
- BCAB $11,000,000.00
- NOM N/A
- Revenue This Year
- BCAB N/A
- NOM N/A
- Revenue Next Year
- BCAB N/A
- NOM N/A
- P/E Ratio
- BCAB N/A
- NOM N/A
- Revenue Growth
- BCAB N/A
- NOM N/A
- 52 Week Low
- BCAB $0.24
- NOM $8.52
- 52 Week High
- BCAB $2.53
- NOM $10.48
- Technical
- Relative Strength Index (RSI)
- BCAB 66.59
- NOM 49.81
- Support Level
- BCAB $0.63
- NOM $10.90
- Resistance Level
- BCAB $0.89
- NOM $11.19
- Average True Range (ATR)
- BCAB 0.07
- NOM 0.16
- MACD
- BCAB 0.00
- NOM -0.02
- Stochastic Oscillator
- BCAB 70.47
- NOM 30.43
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in the United States. The Fund's investment objective is current income exempt from both regular federal income taxes and Missouri personal income taxes, and to enhance portfolio value relative to the Missouri municipal bond market by investing in tax-exempt Missouri municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund invests in municipal securities as well as floating rate securities, and derivatives such as futures, options, and swap contracts to the necessary extent.